This editorial refers to 'Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis' † , by F. Ruschitzka et al., on page 3282.
Inhibition of COX-1 will inhibit platelet aggregation. Inhibition of COX-2 will inhibit prostacyclin, which may increase thrombotic risk. Non-selective NSAIDs will act on both pathways. COX-2 inhibitors may increase the risk of cardiovascular events by inhibiting prostacyclin synthesis without the benefit of platelet inhibition. However, COX-2 inhibitors may also reduce risk by inhibition of vascular inflammation and thereby enhance coronary plaque stability. COX-1 is also present in the gastric mucosa, and inhibition has been shown to result in gastrointestinal side effects. The development of specific COX-2 inhibition offered the possibility of reduced gastric side effects, but with the potential of increased cardiovascular risk.
The safety of COX-2 inhibitors became of increased concern after publication of two trials with rofecoxib. In the VIGOR trial, 8076 patients with rheumatoid arthritis were randomized to rofecoxib 10 mg daily or naproxen 500 mg twice a day. 6 There was a lower incidence of gastrointestinal toxicity with rofecoxib. However, the incidence of myocardial infarction was lower with naproxen [0.1% vs.
The increased cardiovascular risk with rofecoxib was confirmed in the APPROVe trial, in which 2586 patients with colorectal adenomas were randomized to rofecoxib 25 mg a day or placebo. 7 There were 46 patients with thrombotic events in the rofecoxib group vs. 26 in the placebo group (RR 1.92, 95% CI 1.19-3.11, P = 0.008). Rofecoxib was rapidly removed from the market, with celecoxib the only remaining COX-2 inhibitor in most of the world.
The safety of celecoxib was assessed in the CLASS trial, in which 8059 patients with osteoarthritis or rheumatoid arthritis were randomized to celecoxib 400 mg twice a day, ibuprofen 800 three times a day, or diclofenac 75 mg twice a day. 8 There were fewer gastrointestinal side effects with celecoxib, with no difference in cardiovascular events. However, the follow-up period was only 6 months, and the overall incidence of cardiovascular events was low. The safety of celecoxib continued to be uncertain. The issue of cardiovascular safety with celecoxib was raised several years later in the Adenoma Prevention with Celecoxib (APC) trial in which 2035 patients with a history of colorectal neoplasia were randomized to celecoxib 200 or 400 mg twice daily or placebo. 9 A composite of cardiovascular death, myocardial infarction, stroke, or heart failure was reached in 7 of 679 on placebo (1.0%), 16 of 685 on celecoxib 200 mg twice daily [2.3%; hazard ratio (HR) 2.3, 95% CI 0.9-5.5], and 23 of 671 on celecoxib 400 mg twice daily (3.4%, HR 3.4, 95% CI 1.4-7.8), resulting in early trial termination. While the number of events was small, concern was raised, in particular about the higher dose of celecoxib. The cardiovascular safety of celecoxib compared with nonselective NSAIDs was further investigated in the PRECISION trial, in which 24 081 patients with osteoarthritis or rheumatoid arthritis and who were also at increased cardiovascular risk were randomized to celecoxib (mean 209 mg/day), naproxen (mean 852 mg/day), or ibuprofen (mean 2045 mg/day). 10 The mean duration of therapy was 20.3 months, with mean follow-up 34 months. The primary endpoint was the composite of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke. During the trial, 68.8% of patients stopped the study drug and 27.4% discontinued follow-up. In the intention-to-treat analysis, the primary event occurred in 188 (2.3%), 201 (2.5%), and 218 (2.7%) patients treated with celecoxib, naproxen, and ibuprofen, respectively (P < 0.001 for non-inferiority).
More detailed results also showed no difference between groups for most cardiovascular events. However, the rate of hospitalization for hypertension was lower with celecoxib than with ibuprofen (HR 0.60, 95% CI 0.36-0.99, P = 0.04), but not lower than with naproxen. While the results for the on-treatment analysis were generally similar, the on-treatment mortality was lower with celecoxib than with The current issue of the journal adds to our understanding of the safety of NSAIDs in a substudy of PRECISION concerned with the effect of ibuprofen, naproxen, and celecoxib on blood pressure.
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This was a double-blind, randomized trial of 545 patients at increased cardiovascular risk, with analysable data in 444 patients, 92% with osteoarthritis, and 8% with rheumatoid arthritis. The definition of high risk is detailed in the online appendix to the PRECISION trial. In brief, these are patients with one of the following: coronary disease, occlusive disease of non-coronary arteries, diabetes (type I or II), or multiple risk factors (including older age, history of hypertension, dyslipidaemia, family history of vascular disease, current cigarette smoking, microalbuminuria, left ventricular hypertrophy, reduced ankle-brachial index, or elevated waist-hip ratio). They were randomized to celecoxib (100-200 mg b.i.d.), ibuprofen (600-800 mg b.i.d.), or naproxen (374-500 mg b.i.d.). At 4 months, the mean 24-h systolic blood pressure change was -0.3 mmHg (95% CI -2.25 to 1.74), þ3.7 mmHg (95% CI 1.72-5.58), and þ1.6 mmHg (95% CI -0.40 to 3.57) with celecoxib, ibuprofen, and naproxen, respectively. These changes reflected differences of -3.9 mmHg (P = 0.009) between celecoxib and ibuprofen, -1.8 mmHg (P = 0.12) between celecoxib and naproxen, and of -2.1 mmHg (P = 0.08) between naproxen and ibuprofen. These differences were generally consistent across subgroups, including baseline aspirin, concomitant ACE inhibitor/ARB, sex, race, baseline hypertension, baseline diabetes, and baseline chronic kidney disease. Of patients with normal baseline blood pressure, hypertension (mean 24-h systolic blood pressure > _130 mmHg and/or diastolic blood pressure > _80 mmHg) developed in 10.3% with celecoxib, 23.2% with ibuprofen, and 19.0% with naproxen [compared with celecoxib, odds ratio (OR) 0.39, P = 0.004, and OR 0.49, P = 0.03 for ibuprofen and naproxen, respectively]. Celecoxib resulted in lower blood pressure and less new hypertension than ibuprofen. The results compared with naproxen were equivocal.
The major limitations of this study are acknowledged by the authors. The dose of celecoxib, 200 mg daily in almost all patients in PRECISION overall and in this substudy, may not be sufficient to note cardiac toxicity of celecoxib. However, there was a similar analgesic effect across groups. There was no placebo arm, which would have provided valuable information both in PRECISION overall as well as in this substudy. However, this would not have been ethical in these symptomatic patients with arthritis. It is unfortunate that 16% of patients did not have blood pressure measurement at month 4, and dropouts were higher with ibuprofen.
The PRECISION trial overall and the blood pressure substudy are reassuring regarding the safety of celecoxib at lower doses (see Table 1 for a summary). In this regard, there does seem to be a difference in safety profile between celecoxib and rofecoxib. However, there remain limited long-term randomized trial data compared with placebo, and such data are unlikely to be forthcoming. Indeed, it is not likely that another large trial comparing non-specific and specific COX-2 inhibitor NSAIDs will be conducted. It would of interest to see data with a higher dose of celecoxib, but the doses in PRECISION are probably compatible with current practice. It would have been best if there was greater adherence in the trial, but this too is consistent with practice. Unlike statins or blood pressure medications, patients are not expected to stay on analgesic medication for life. Some more information about safety can be gleaned from non-randomized data, but the treatment selection bias, especially compared with placebo, is likely to be significant. Thus, treatment decisions will need to be made on the basis of the data we have. Safety data tend to favour low-dose celecoxib over non-selective NSAIDs, especially ibuprofen. However, we cannot give any NSAID a perfect recommendation regarding safety, and use should be considered with caution.
Conflict of interest: none declared. There is a lack of long-term randomized trial safety data comparing NSAIDs with placebo Celecoxib as well as all NSAIDs should be used with caution Figure 1 Summary of the cyclooxygenase pathways. Arachidonic acid under the action of the isozyme family COX yields multiple prostaglandins. The COX-1 pathway is constitutive, or physiological for functioning of platelets, the gastrointestinal (GI) mucosa, the kidneys, and other organs. COX-2 is inducible by multiple factors, resulting in inflammation, neoplasia, and prostacyclin production. Blockage of COX-1 can be therapeutic in inhibiting platelets, but can result in GI side effects and elevated blood pressure. Inhibition of COX-2 can be therapeutic in relieving pain due to inflammation and potentially in decreasing neoplasia. However, blockage of COX-2 may lead to decreased prostacyclin production, causing vasoconstriction and increased platelet aggregation.
